1. Desembre 2013
Actualització
farmacoterapèutica
en Esclerosi Múltiple
@APR_300

2. Presentació
Objectiu: recollir les novetats sobre farmacoteràpia de l’Esclerosi Múltiple
publicats en les diferents revistes biomèdiques. En aquest document, hi podràs
trobar reunits els tuits de cada mes del compte de Twitter @APR_300 per a una
lectura més fàcil.
La present informació està dirigida a professionals sanitaris. En cas que siguis
un pacient, comenta qualsevol dubte amb un professional sanitari.
Tipus d’informació: orientat a la farmacoteràpia i aspectes relacionats com la
farmacogenètica o la farmacoeconomia i també alguns estudis de recerca
bàsica.
Filtre d’idioma: articles publicats en anglès, català o castellà.
No hi ha conflictes d’interessos.
No es pretén afavorir a cap fàrmac. El volum d’informació de cada apartat
dependrà exclusivament del nombre d’articles publicats/ localitzats.
Autora:
Ariadna Pérez Ricart
Farmacèutica hospitalària
Twitter: @APR_300
Desembre 2013. Vol 1, Núm 2
@APR_300
Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

3. Aquest mes, notícies sobre:
-Interferons
-Acetat de
glatiràmer
-Fingolimod
-Natalizumab
-Laquinimod
-Daclizumab
-Alemtuzumab
-Rituximab
-Vitamina D
-Espasticitat
-Vacuna Bacille
Calmette-Guérin
-4-aminopiridina
-Dalfampridine
Fampridine
/
-Genètica
-Pediatria
-Embaràs
Desembre 2013. Vol 1, Núm 2
@APR_300
Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

4. DESEMBRE 2013
Esdeveniments destacats:
15 de desembre: La Marató de TV3.
Malalties neurodegeneratives.
18 de desembre: Dia Nacional de l’Esclerosi
Múltiple
Tuits:
Interferons
- Intramuscular IFNß-1a in multiple sclerosis: ‘no proof of effectiveness’ or ‘proof of
no effectiveness’? http://bit.ly/18wkXdD Eur J Neurol
- Assessing treatment response to interferon-β http://bit.ly/1cEgRPn Neurology
- ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for
multiple sclerosis: a prospective European study http://1.usa.gov/19BRVnm Med
Devices
- Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with
interferon-beta-1b: a case report. http://bit.ly/19ymfTF J Med Cas Rep
-Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised
controlled trial of patients with clinically isolated syndromes http://bit.ly/1jNpvyr J Neur
Neurosurg Psychiatry
-Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of
BENEFIT. http://bit.ly/19fKyb2 J Neur Neurosurg Psychiatry
Acetat de glatiràmer
-Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple
sclerosis and in delaying the onset of clinically definite multiple sclerosis.
http://bit.ly/1cjLwkZ CNS Drugs
Desembre 2013. Vol 1, Núm 2
@APR_300
Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

5. Fingolimod
-Five-year results from a phase 2 study of oral fingolimod in relapsing remiting
multiple sclerosis http://bit.ly/18Sp2GV Mult Scler
- Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for
relapse rates in multiple sclerosis: a retrospective US claims database analysis
bit.ly/1eDV8Xr Curr Med Res Opin
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world
relapsing multiple sclerosis population: a phase 3b, open-label study
http://bit.ly/1eQkB0C J Neurol
- Fingolimod-induced atrioventricular conduction defects in a young lady with multiple
sclerosis via CIMSFHUVH http://bit.ly/1czgHc8 Eur J Clin Pharmacol
Natalizumab
- Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial
multiple sclerosis http://bit.ly/1bc3xx1 Eur J Neurol
-Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly
demanding tango http://bit.ly/1iwlFeO Expert Opin Biol Ther
-A benefit-risk analysis of natalizumab in the treatment of pa tients with multiple
sclerosis when considering the risk of progressive multifocal leukoencephalopathy
http://bit.ly/1bGGj8w Curr Med Res Opin
-Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients
http://bit.ly/J2RmMh Mult Scler
- Recurrent disease-activity rebound in a patient with multiple sclerosis after
natalizumab discontinuations for pregnancy planning http://bit.ly/1aLolLV Mult Scler
- Smokers run increased risk of developing anti-natalizumab antibodies
http://bit.ly/IPnN0G Mult Scler
- Risk acceptance in multiple sclerosis patients on natalizumab treatment.
http://bit.ly/1c1hliE Plos One
- Consenso español actualizado sobre el uso del natalizumab via CIMSFHUVH i
BibliotecaHUVH http://bit.ly/1c3hrpT Neurologia
Laquinimod
-Multiple sclerosis: Oral laquinimod for MS—bringing the brain into focus
http://bit.ly/1gJIvLU Nature Reviews Neurology
Desembre 2013. Vol 1, Núm 2
@APR_300
Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

6. Daclizumab
-Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis
http://bit.ly/1d3qrtn Expert Rev Clin Pharmacol
- Assessing dalfampridine efficacy in the physician’s office http://bit.ly/1bN5Kz6 Mult
Scler
- Effect of daclizumab high-yield process in patients with highly active relapsingremitting multiple sclerosis http://bit.ly/19UK7RA J Neurol
Alemtuzumab
-Current evaluation of alemtuzumab in multiple sclerosis. http://bit.ly/1g3vjUk Expert
Opin Biol Ther
Rituximab
-Rituximab for relapsing-remitting multiple sclerosis. http://bit.ly/199urtv Cochrane
Database Syst Rev
Vitamina D
-1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS
localization. http://1.usa.gov/1bWqV7Z Proc Nat Acad SCI USA
Tractaments simptomàtics
-Bladder management in MS http://bit.ly/1bDvp1A Phys Med Rehabil Clin N Am
-Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility
improvement study (Move I) http://bit.ly/1dYNxq3 Eur J Health Econ
- Vision and multiple sclerosis http://bit.ly/IzkLya Multiple Sclerosis & related
disorders
-Pharmacological treatment for memory disorder in multiple sclerosis Cochrane
Database Syst Rev http://bit.ly/1cl0REV
-4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
http://bit.ly/1e3AQ91 Ther Adv Neurol Disord
- Evidence-based guideline: Assessment and management of psychiatric disorders in
individuals with MS http://bit.ly/KeX8LM Neurology
Desembre 2013. Vol 1, Núm 2
@APR_300
Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

7. Tractaments simptomàtics
-Espasticitat
-Correlation between spasticity and quality of life in patients with multiple sclerosis:
the
CANDLE
study
http://bit.ly/1b8DY3j
Int
J
Neurosci
-MultipleSclerosis spasticity epidemiology – key publications. http://bit.ly/1hryKEX
Exp
Rev
Neurother
-MultipleSclerosis spasticity management – key publications http://bit.ly/1j8StbM Exp
Rev
Neurother
-Advances in the management of multiple sclerosis spasticity: experiences from
recent studies and everyday clinical practice http//bit.ly/IDkRVK Exp Rev Neurother
-Advances in the management of MultipleSclerosis spasticity: guidelines
http://bit.ly/1b6YrXk
Exp
Rev
Neurother
-Clinical case reviews in multiple sclerosis spasticity: experiences from around
Europe http://bit.ly/1cgatOm Exp Rev Neurother
-Dalfampridine / Fampridine
-Pharmacokinetic profile of dalfampridine extended release: clinical relevance in
patients with multiple sclerosis http://bit.ly/18vTo47 Curr Med Res Opin
-Long-term effects of dalfampridine in patients with multiple sclerosis.
http://bit.ly/19fcwxO J Neurol Sci
- Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis
http://bit.ly/1bp3CNO Multiple Sclerosis & related disorders
Transplantament hematopoiètic i noves teràpies
- Identification of Inflammatory Neuronal Injury and Prevention of Neuronal Damage
in Multiple Sclerosis. Hope for Novel Therapies? http://bit.ly/1d6r0T3 JAMA Neurol
-Iron depletion induced by bloodletting and followed by rhEPO administration as a
therapeutic strategy in progressive multiple sclerosis: A pilot, open-label study with
neurophysiological measurements http://bit.ly/1c2T2fK Neurophysiol Clin
-Immunosuppressive therapy reduces axonal damage in progressive multiple
sclerosis http://bit.ly/J2QQxV Mult Scler
- Effects of Bacille Calmette-Guérin vaccine after the first demyelinating event in the
CNS multiple sclerosis http://bit.ly/1bhXln6 Neurology
Genètica
-Decoding multiple sclerosis: an update on genomics and future directions
http://bit.ly/19chLOE Expert Rev Neurother
-Body fluid biomarkers in multiple sclerosis http:// bit.ly/1gjp8f1 Lancet Neurol
Desembre 2013. Vol 1, Núm 2
@APR_300
Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

8. Pediatria i Embaràs
- Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis
and immune-mediated central nervous system demyelination disorders
http://bit.ly/1cubeDo J Neurol Neurosurg Psychiatry
-Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying
Drugs for multiple sclerosis http://bit.ly/19aPSfS CNS Drugs
Altres
-Esclerosis múltiple en el contexto español http://bit.ly/1eIIVkd Rev Neurol
-Risk
evaluation
and
monitoring
in
multiple
sclerosis
therapeutics
http://bit.ly/18SpCEL Mult Scler
-Multiple sclerosis and related disorders: groundbreaking news http://bit.ly/1d4LawM
Lancet Neurol
- Treatment of multiple sclerosis in Germany: an analysis based on claims data of
more than 30,000 patients http://bit.ly/1bvI4PT Int J Clin Pharm
- A network meta-analysis of randomized controlled trials comparing the
effectiveness and safety profile of treatments for relapsing multiple sclerosis via
CIMSFHUVH http://bit.ly/1bMESQ3 J Clin Pharm Ther
-New and emerging immune-targeted drugs for the treatment of multiple sclerosis.
http://bit.ly/18BAfxn Br J Clin Pharmacol
-Optimizing therapeutics in the management of patients with multiple sclerosis: a
review of drug efficacy, dosing, and mechanisms of action. http://bit.ly/1dwuWg7
Biologics
- Novel Immunomodulatory Approaches for the Management of multiple sclerosis via
@velezmeca http://bit.ly/1l0MJyJ Clin Pharmacol Ther
- Antimyelin antibodies as predictors of disability after clinically isolated syndrome
http://bit.ly/1e65OgI Int J Neurosci
-Impact of delayed diagnosis and treatment in clinically isolated syndrome
and multiple sclerosis http://bit.ly/19aFO46 J Neurosci Nurs
Desembre 2013. Vol 1, Núm 2
@APR_300
Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.

9. Pacients
-Esclerosis multiple en linea: Incontinencia urinaria. Vídeos per a pacients de
@FundacioGaem
-RT@neurodidacta: embarazo, lactancia o anticoncepción en esclerosis múltiple de
la Dra Mar Mendibe http://bit.ly/IowXS8 vía @redpacientes
-RT@VHIR_:El Dr. @XMontalban encercla l'esclerosi múltiple a Càpsules de Ciència
Televisió de Catalunya: http://bit.ly/1cSOk6Z via @tv3cat
-Lazo Múltiple: app per la difusió i la conscienciació sobre l'Esclerosis Múltiple
http://bit.ly/1g7zKhd
Agències de medicaments i altres notícies
-Review of Dimethyl fumarate http://bit.ly/1eMhnKF AustPrescriber
- Estudio de la retina para visualizar la evolución de la esclerosis múltiple via
seneurologia http://bit.ly/1aPrD0L
- La vitamina D podria aliviar los síntomas de la EM via fundcerebro
http://bit.ly/18Ujnm2
Desembre 2013. Vol 1, Núm 2
@APR_300
Este obra está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional.